Symptomatic arrhythmia recurrence as an outcome in clinical trials of antiarrhythmic drug therapy

Heart Rhythm

Volumn 1, Issue 2 SUPPL., 2004, Pages 36-40

  Pritchett, Edward L C ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Antiarrhythmic drugs; Arrhythmias; Atrial fibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; DIGOXIN; FLECAINIDE ACETATE; PLACEBO; PROPAFENONE; SOTALOL; VERAPAMIL;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG LEGISLATION; DRUG RELEASE; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DOCUMENTATION; OUTCOMES RESEARCH; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; RECORDING; RECURRENT DISEASE; SUSTAINED DRUG RELEASE; SYMPTOMATOLOGY; UNITED STATES;

EID: 3042773837     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2004.04.005     Document Type: Article

References (19)

1. Psaty B.M. Manolio T.A. Kuller L.H. Kronmal R.A. Cushman M. Fried L.P. White R. Furberg C.D. Rautaharju P.M. Incidence of and risk factors for atrial fibrillation in older adults Circulation 96 1997 2455-2461
2. Bhandari A.K. Alpert B.L. Cullen J. Pritchett E.L.C. Flecainide Supraventricular Tachycardia Study Group Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study Am Heart J 124 1992 381 386
3. Pritchett E.L.C. Hammill S.C. Reiter M.J. Lee K.L. McCarthy E.A. Zimmerman J.M. Shand D.G. Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia Am J Cardiol 52 1983 1007-1012
4. Anderson J.L. Gilbert E.M. Alpert B.L. Henthorn R.W. Waldo A.L. Bhandari A.K. Hawkinson R.W. Pritchett E.L.C. Flecainide Supraventricular Tachycardia Study Group Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring Circulation 80 1989 1557-1570
5. Henthorn R.W. Waldo A.L. Anderson J.L. Gilbert E.M. Alpert B.L. Bhandari A.K. Hawkinson R.W. Pritchett E.L.C. Flecainide Supraventricular Tachycardia Study Group Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia Circulation 83 1991 119-125
6. Cobbe S.M. Rae A.P. Poloniecki J.D. UK Propafenone PSVT Study Group A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation Circulation 92 1995 2550-2557
7. Pritchett E.L.C. McCarthy E.A. Wilkinson W.E. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, cross-over trial in patients tolerating oral therapy Ann Intern Med 114 1991 539-544
8. Benditt D.G. Williams J.H. Jin J. Deering T.F. Zucker R. Browne K. Chang-Sing P. Singh B.N. dl-Sotalol Atrial Fibrillation/Flutter Study Group Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter Am J Cardiol 84 1999 270-277
9. Pritchett E.L.C. Page R.L. Connolly S.J. Marcello S.R. Schnell D.J. Wilkinson W.E. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators Antiarrhythmic effects of azimilide in atrial fibrillation. Efficacy and dose-response J Am Coll Cardiol 36 2000 794-802
10. Pritchett E.L.C. Page R.L. Carlson M. Undesser K. Fava G. Rythmol Atrial Fibrillation Trial (RAFT) Investigators Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation Am J Cardiol 92 2003 941-946
11. Roy D. Talajic M. Dorian P. Connolly S.J. Eisenberg M.J. Green M. Kus T. Lambert J. Dubuc M. Gagne P. Nattel S. Thibault B. Canadian Trial of Atrial Fibrillation Investigators Amiodarone to prevent recurrence of atrial fibrillation N Engl J Med 342 2000 913-920
12. Meinertz T. Lip G.H.Y. Lombardi F. Sadowski Z.P. Kalsch B. Camez A. Hewkin A. Eberle S. The ERAFT Investigators Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study) Am J Cardiol 90 2002 1300-1306
13. Pritchett E.L.C. Evolution and revolution in drug labeling: regulation of antiarrhythmic drugs by the Food and Drug Administration 1962-1996 Pacing Clin Electrophysiol 21 1998 1457-1469
14. Epstein A.E. Hallstrom A.P. Rogers W.J. Liebson P.R. Seals A.A. Anderson J.L. Cohen J.D. Capone R.J. Wyse D.G. CAST Investigators Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction JAMA 270 1996 2451-2455
15. AFFIRM I. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825-1833
16. Pritchett E.L.C. Smith M.S. McCarthy E.A. Lee K.L. The spontaneous occurrence of paroxysmal supraventricular tachycardia Circulation 70 1984 1-6
17. Sintetos A.L. Roark S.F. Smith M.S. McCarthy E.A. Lee K.L. Pritchett E.L.C. Incidence of symptomatic tachycardia in untreated patients with paroxysmal supraventricular tachycardia Arch Intern Med 146 1986 2205-2209
18. Page R.L. Wilkinson W.E. Clair W.K. McCarthy E.A. Pritchett E.L.C. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia Circulation 89 1994 224-227
19. Page R.L. Tilsch T.W. Connolly S.J. Schnell D.J. Marcello S. Wilkinson W.E. Pritchett E.L.C. Azimilide Supraventricular Arrhythmia Program Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide Circulation 107 2003 1141-1145